Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A designer pore-blocking peptide reveals an electrostatic complementation mechanism for the inhibition-resistant Kv1.5 channel.

Created on 05 Sep 2026

Authors

Ruiming Zhao, Maha Nayak, Rong Shen, Hui Dai, Punyanuch Hua, Eduardo Perozo, Steve A N Goldstein

Published in

Science advances. Volume 12. Issue 36. Pages eaef6020. Sep 04, 2026. Epub Sep 04, 2026.

Abstract

Most voltage-gated potassium (Kv) channels are inhibited by peptide neurotoxins that occlude the pore with a positively-charged lysine. Kv1.5 repels these toxins electrostatically via four arginines (R487), one on each pore-forming subunit. Here, we describe chimera toxin (CmTx), a potent and selective blocker that prefers the slow-inactivated Kv1.5 conformation promoted by rapid firing and acidosis (Ki = 127 nM), conditions associated with atrial fibrillation and ischemia. CmTx was isolated by cell-based, phage-display library panning of de novo peptides engineered on a SAK1 scaffold and shows minimal inhibition of seven other Kv subtypes. Scanning mutagenesis identified CmTx and Kv1.5 residues essential to binding. AlphaFold modeling shows how acidic CmTx residues can neutralize the channel arginines, enabling one peptide to plug the Kv1.5 pore. These findings present an electrostatic pore-blocking mechanism driven by complementary charge interactions and offer CmTx as a tool to probe Kv1.5 physiology and a potential therapeutic lead.

PMID:
42696590
Bibliographic data and abstract were imported from PubMed on 05 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement